fluorouracil topical / Generic mfg. - LARVOL DELTA

Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. (PubMed, J Nutr) - P1/2 | "Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer. This trial was registered at clinicaltrials.gov as NCT01490996 and at www.clinicaltrialsregister.eu as EudraCT 2011-002289-19."

Clinical • Journal • P2a data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Topical Fluorouracil Therapy for Residual Superficial Basal Cell Carcinoma following Mohs Micrographic Surgery: A Long-Term Follow-Up Study (AAD 2026) - "Our study demonstrates the effectiveness of using topical 5-FU as an alternative adjuvant therapy for clearance of residual sBCC in patients with surgical fatigue. Future studies ought to include more diverse patient populations to generalize our findings to a wider population base."

Surgery • Basal Cell Carcinoma • Genetic Disorders • Non-melanoma Skin Cancer • Oncology • Skin Cancer

Topical 5-Fluorouracil and Topical 5-Fluorouracil/Calcipotriene in Allogeneic Stem Cell Transplant Recipients: Safety and Efficacy (AAD 2026) - "Topical 5-FU and 5-FU/C appear safe in allo-HSCT recipients, with no increased risk of GVHD flares. 5-FU demonstrated high efficacy, particularly for SCCIS, whereas 5-FU/C responses were lower than previously reported for immunocompetent patients. These findings support the cautious use of topical 5-FU and 5-FU/C in this high-risk population and warrant prospective studies."

Clinical • Actinic Keratosis • Basal Cell Carcinoma • Bone Marrow Transplantation • Bowens Disease • Graft versus Host Disease • Immunology • Non-melanoma Skin Cancer • Squamous Cell Carcinoma • Transplantation

The additive effect of melatonin on 5-fluorouracil–mediated HaCaT cell death (AAD 2026) - "Topical 5-fluorouracil is an effective treatment of actinic keratosis but its cytotoxicity result in side effects that reduce patient compliance. High concentrations of melatonin increase the cell-death achieved by 5-flourouracil. Whether adding melatonin could reduce the concentration of 5-fluorouracil in a clinical setting needs further evaluation."

Actinic Keratosis

Topical 5-Fluorouracil and Photodynamic Therapy: Distinct Clonal Size–Dependent Effects on the Epidermis (AAD 2026) - "PDT and 5-FU exhibit distinct, clone size–dependent effects on epidermal CMs: PDT modestly favors removal of larger clones, whereas 5-FU strongly targets smaller clones. These findings highlight fundamental differences between two field treatments in eliminating precancerous clones to optimize field treatments strategies for tumorigenesis prevention."

Actinic Keratosis • Genetic Disorders • Skin Cancer

Real World Evidence of Clinical Clearance and 3-Year Recurrence Rates of Non-Melanoma Skin Cancer with Photodynamic Therapy (AAD 2026) - "FDA-approved treatments include Mohs micrographic surgery, excision, electrodessication and curettage, topical imiquimod, and topical fluorouracil. After 3 years, 72% of NMSCs maintained clearance, with 3% recurrence, and 24% lost to follow-up. Further retrospective and prospective real-world experience studies with long-term recurrence data on a larger number of NMSCs are needed to characterize the efficacy and durability of PDT monotherapy."

Clinical • HEOR • Real-world • Real-world evidence • Actinic Keratosis • Basal Cell Carcinoma • Bowens Disease • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

Management of Non-Melanoma Skin Cancer During Pregnancy: A Retrospective TriNetX Study (AAD 2026) - "Topical 5-fluorouracil included 1,935 pregnant and 1,938 non-pregnant patients, with risks of 2.377% vs. 2.528% (p = 0.7611). Imiquimod included 1,931 pregnant and 1,934 non-pregnant patients, with risks of 2.02% vs. 2.017% (p = 0.9945)...These results suggest that pregnancy does not significantly alter management, though careful consideration of surgical guideline adherence remains essential for Mohs. Further prospective studies may be warranted to explore treatment strategies."

Retrospective data • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor

Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: A multicenter randomized controlled trial (AAD 2026) - No abstract available

Clinical • Bowens Disease

U045 Field Cancerization Therapies: Medical Dermatology and Beyond (AAD 2026) - "This session will outline the standard of care field therapies including and not limited to topical 5- fluorouracil, imiquimod, conventional/daylight photodynamic therapy, lasers, peels and other modalities. 3. Select the right candidates for field directed therapies and for a variety of cutaneous entities."

Actinic Keratosis • Dermatology • Oncology

NRG-HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA (clinicaltrials.gov) - P2/3 | N=685 | Active, not recruiting | Sponsor: NRG Oncology | Trial primary completion date: Feb 2026 ➔ Feb 2027

Biomarker • Trial primary completion date • Epstein-Barr Virus Infections • Head and Neck Cancer • Infectious Disease • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - P3 | N=290 | Active, not recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Recruiting ➔ Active, not recruiting

Enrollment closed • Head and Neck Cancer • Hypopharyngeal Cancer • Laryngeal Cancer • Oncology • Oral Cancer • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer

Frequency of non-melanoma skin cancer (NMSC) patients with more than one germline mutation and case report of a novel triple mutant in DNA repair genes associated with very high frequency skin cancers (AAD 2026) - "We provide an example of chemoprevention with on-label topical 5-fluorouracil and off-label acitretin to lower her NMSC incidence by >70%. We anticipate that germline testing platform usage will increase in the coming decades, leading to more patients testing positive for more than one pathogenic mutation. Optimal management of these patients depends on the combination of germline mutations and phenotypes. Management may require careful consideration of combination and/or off-label treatment (5, 6) due to lack of guidance or systematic data in the literature."

Case report • Clinical • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • BRCA1 • MSH3 • MUTYH

Beyond Survival: Managing Multiple Cutaneous Squamous Cell Carcinomas In a Patient with History of Acute Lymphoblastic Leukemia (AAD 2026) - "She's also had multiple clinically suspicious premalignant lesions treated with topical 5-fluorouracil (5-FU)...Numerous studies have documented treating early-stage SCC with intralesional 5-FU, methotrexate, and bleomycin. Intralesional PD-1 antibody cemiplimab is currently under investigation showing promising efficacy data. With rising HCT rates in pediatrics, the burden of KC in this vulnerable population is unlikely to diminish despite evolving therapies. Given limited data, it is essential for dermatologists to employ patient-centered, evidence-based approaches and engage in shared decision-making when navigating treatment options for these complex cases."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Non-melanoma Skin Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

A Rare Case of Pityriasis Rubra Pilaris Triggered by Topical Fluorouracil (AAD 2026) - "Pityriasis rubra pilaris (PRP) is a rare, chronic inflammatory skin disorder with an uncertain etiology; however, triggers can include infection, vaccines and medications. This case suggests a possible association between 5-FU and the onset of PRP. With 12 months of monitoring, this case provides data for the longitudinal effectiveness of using secukinumab and its success in treating PRP."

Clinical • Actinic Keratosis • CNS Disorders • Depression • Infectious Disease • Inflammation • IL17A

Beyond the Scalpel: Conservative Management of Eruptive Keratoacanthomas in a Geriatric Case (AAD 2026) - "Given her age, comorbidities, and lesion distribution, a multimodal regimen was used: topical 5-fluorouracil 5% with calcipotriol under occlusion (Monday–Friday, six weeks), oral nicotinamide (500 mg twice daily), daily medium-compression stockings, and systemic acitretin (10 mg/day, increased to 20 mg/day after two months). This case demonstrates that a multimodal, non-surgical regimen offers a safe and effective alternative for managing eruptive KAs in elderly patients with surgical contraindications."

Clinical • Dry Eye Disease • Ophthalmology • Squamous Cell Carcinoma

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Arjun Mittra | Trial completion date: Jan 2026 ➔ Sep 2026 | Trial primary completion date: Jan 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Feb 2026 ➔ Feb 2028 | Trial primary completion date: Feb 2026 ➔ Feb 2028

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: University of Chicago | Trial completion date: Jan 2026 ➔ Jan 2028 | Trial primary completion date: Jan 2026 ➔ Jan 2028

Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-1 • PD-L1

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy (clinicaltrials.gov) - P1/2 | N=60 | Not yet recruiting | Sponsor: Mayo Clinic

New P1/2 trial • Colon Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Efficacy of Topical 5-Fluorouracil Combined with Microneedling in the Treatment of Stable Vitiligo. (PubMed, J Coll Physicians Surg Pak) - "The use of topical 5-Fluorouracil in combination with microneedling is an effective treatment for stable vitiligo."

Journal • Dermatology • Immunology • Vitiligo

ATOMIC: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - P3 | N=700 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Apr 2025 ➔ Jan 2028 | Trial primary completion date: Apr 2025 ➔ Jan 2028

Mismatch repair • Trial completion date • Trial primary completion date • Tumor mutational burden • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Genetic Disorders • Oncology • Solid Tumor • CD4 • MLH1 • MSH2 • MSH6 • MSI

ATOMIC: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - P3 | N=700 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2021 ➔ Apr 2024 | Trial primary completion date: Dec 2021 ➔ Apr 2024

Mismatch repair • Trial completion date • Trial primary completion date • Tumor mutational burden • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genetic Disorders • Oncology • Solid Tumor • CD4 • MLH1 • MSH2 • MSH6 • MSI

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - P1 | N=38 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Active, not recruiting

Enrollment closed • Colorectal Cancer • Oncology • Solid Tumor • PIK3CA • PTEN

ATOMIC: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - P3 | N=700 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2020 ➔ Dec 2021 | Trial primary completion date: Dec 2020 ➔ Dec 2021

Mismatch repair • Trial completion date • Trial primary completion date • Tumor mutational burden • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genetic Disorders • Oncology • Solid Tumor • CD4 • MLH1 • MSH2 • MSH6 • MSI

ATOMIC: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - P3 | N=700 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2020 ➔ Dec 2020 | Trial primary completion date: Jul 2020 ➔ Dec 2020

Mismatch repair • Trial completion date • Trial primary completion date • Tumor mutational burden • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genetic Disorders • Oncology • Solid Tumor • CD4 • MLH1 • MSH2 • MSH6 • MSI